---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Special populations"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Special populations. Topics: Renal impairment: minor renal elimination, Renal impairment: single-dose study in severe renal impairment, Renal function range enrolled in AMPLITUDE, Hepatic impairment: single-dose study in mild or moderate hepatic impairment, and 8 further topics. 12 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/special-populations"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Renal impairment: minor renal elimination

> “Renal clearance is a minor elimination pathway; thus, no dose adjustment is anticipated for the intended patient population that is expected to include patients with renal function impairment.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.8-2"></a>

### Renal impairment: single-dose study in severe renal impairment

> “The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of Inaxaplin (IXP) in participants with severe renal impairment and healthy participants with normal renal function.”
> “Stable renal function for at least 1 month prior to enrollment”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-2.1.2.8-3"></a>

### Renal function range enrolled in AMPLITUDE

> “Estimated glomerular filtration rate (eGFR) ≥25 to < 75 mL/min/1.73 m2 during the Screening Period”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.8-4"></a>

### Hepatic impairment: single-dose study in mild or moderate hepatic impairment

> “The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of Inaxaplin (IXP) in participants with mild or moderate hepatic impairment and in matched healthy participants.”
> “Cohort 1 (mild impairment): defined as a Child-Pugh total score of 5 to 6 (Child-Pugh Class A)”
> “Cohort 3 (moderate impairment): defined as a Child-Pugh total score of 7 to 9 (Child-Pugh Class B)”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-2.1.2.8-5"></a>

### Hepatic laboratory exclusions in AMPLITUDE

> “Total bilirubin ≥1.5 × upper limit of normal (ULN)”
> “Aspartate transaminase (AST) or alanine transaminase (ALT) ≥2 × ULN”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.8-6"></a>

### Pediatric population: adolescents added to the phase 3 portion of AMPLITUDE

> “In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.”
> “The IDMC also recommended enrolling adolescents with AMKD ages 10 to 17 years in the Phase 3 portion of the study.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

> “For Phase 3, subjects must be between the ages of 12 and 65 years at time of signing first ICF, inclusive.”
> “Pediatric subjects may be enrolled only after IDMC review of Phase 2 data is completed, the Phase 3 dose is selected, and a recommendation by the IDMC on the inclusion of pediatric subjects is made.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.8-7"></a>

### Pediatric population: acceptability of the tablet formulation

> “Part A: Acceptability Tablet Formulation of VX-147 in Pediatric Participants using the Convenience Domain of the Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-2.1.2.8-8"></a>

### Pediatric population: EU paediatric investigation plan

> “EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inaxaplin, (EMEA-003368-PIP01-22)”

Source: [EMA paediatric investigation plan EMEA-003368-PIP01-22 (2023)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003368-pip01-22)

<a id="topic-2.1.2.8-9"></a>

### Older adults: enrollment limit in AMPLITUDE

> “Up to approximately 15% of the total number of subjects planned for enrollment may be >61 to ≤65 years of age at time of signing first ICF, inclusive.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.8-10"></a>

### Pregnancy and childbearing potential: exclusion from the phase 1 studies

> “In both studies, we enrolled healthy men and women of non-childbearing potential who were at least 18 years of age with body weight of >50 kg and body mass index (BMI) 18.0 to 32.0 kg/m2.”
> “A limitation of these studies, like most phase 1 studies, is that participants were predominantly men (owing to exclusion of women of childbearing age).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.8-11"></a>

### Pregnancy and lactation: exclusion from AMPLITUDE

> “Pregnant or nursing female subjects. Females of childbearing potential must have a negative pregnancy test at screening (serum test) and Day 1 (urine test).”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.8-12"></a>

### Contraception requirements in the phase 2a study

> “Methods of contraception must be in successful use from signing of consent, approximately 28 days before the first dose of study drug (unless otherwise noted), and until 90 days following the last dose of study drug.”
> “Male subjects must use a condom to avoid exposing a potential fetus to study drug via the seminal fluid.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

Additional sources: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
